 |
|
Statins and Regression of Coronary Atherosclerosis—Reply
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In Reply: Dr Athyros and colleagues describe the results of the GREACE study, which demonstrated that a small increase in levels of HDL-C independently predicted the clinical benefit observed during administration of atorvastatin in patients with established coronary heart disease.1 This observation highlights a number of important points. Their findings provide further evidence to support the concept that small increases in levels of HDL-C are clinically important. We believe that the beneficial effect of statin therapy is likely derived from several properties beyond the ability of these drugs to lower levels of LDL-C. The findings described by the GREACE investigators also represent an example of the complementary observations between clinical outcomes trials and imaging studies that measure the rate of atheroma progression as assessed by intravascular ultrasound.
Financial Disclosures: Dr Nicholls reported receiving honoraria for lectures from Pfizer, AstraZeneca, and Merck Schering-Plough; consulting fees from AstraZeneca and Anthera Pharmaceuticals; and . . . [Full Text of this Article]
Stephen J. Nicholls, MBBS, PhD
nichols1@ccf.org
E. Murat Tuzcu, MD;
Steven E. Nissen, MD
Department of Cardiovascular Medicine
Cleveland Clinic
Cleveland, Ohio
RELATED LETTER
Statins and Regression of Coronary Atherosclerosis
Vasilios G. Athyros, Anna Kakafika, Asterios Karagiannis, and Dimitri P. Mikhailidis
JAMA. 2007;297(20):2197.
EXTRACT
| FULL TEXT
|
